Literature DB >> 5282950

Aplastic anaemia, acute myeloblastic leukaemia, and oxymetholone.

I W Delamore, C G Geary.   

Abstract

Four patients developed acute myeloblastic leukaemia after treatment of aplastic anaemia with oxymetholone. Two had previously shown an excellent clinical response to the drug and a third some improvement. Though no definite causal relationship between therapy and the onset of leukaemia has been established, the number of cases is greater than might have been expected by chance. The association of the two diseases is discussed.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5282950      PMCID: PMC1796321          DOI: 10.1136/bmj.2.5764.743

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  EFFECT OF OXYMETHOLONE IN REFRACTORY ANEMIA.

Authors:  L SANCHEZ-MEDAL; J PIZZUTO; E TORRE-LOPEZ; R DERBEZ
Journal:  Arch Intern Med       Date:  1964-05

2.  Idiopathic aplastic anaemia. Incidence and management.

Authors:  M C ISRAELS; J F WILKINSON
Journal:  Lancet       Date:  1961-01-14       Impact factor: 79.321

3.  Aplastic anemia: an analysis of 50 cases.

Authors:  D N MOHLER; B S LEAVELL
Journal:  Ann Intern Med       Date:  1958-08       Impact factor: 25.391

4.  Preleukemic acute human leukemia.

Authors:  M BLOCK; L O JACOBSON; W F BETHARD
Journal:  J Am Med Assoc       Date:  1953-07-11

5.  Aplastic anaemia. Review of twenty-seven cases.

Authors:  E B ADAMS
Journal:  Lancet       Date:  1951-03-24       Impact factor: 79.321

6.  Preleukaemia a report of four cases.

Authors:  B E Roberts; C R Abbott; R W Fortt; R D Pyrah
Journal:  Acta Haematol       Date:  1968       Impact factor: 2.195

7.  An analysis of hypoplastic anaemia with special reference to the use of oxymetholone ("Adroyd") in its therapy.

Authors:  S J Silink; B G Firkin
Journal:  Australas Ann Med       Date:  1968-08

8.  Effect of steroids on the cycling of haemopoietic stem cells.

Authors:  J W Byron
Journal:  Nature       Date:  1970-12-19       Impact factor: 49.962

  8 in total
  10 in total

1.  The bone marrow in aplastic anaemia: diagnostic and prognostic features.

Authors:  B Frisch; S M Lewis
Journal:  J Clin Pathol       Date:  1974-03       Impact factor: 3.411

2.  Acute leukaemia after busulphan.

Authors:  H Stott; W Fox; D J Girling; R J Stephens; D A Galton
Journal:  Br Med J       Date:  1977-12-10

3.  Aplastic anemia--and early phase preceding acute lymphatic leukemia.

Authors:  V P Choudhry; R K Adhikari; A K Saraya
Journal:  Indian J Pediatr       Date:  1982 May-Jun       Impact factor: 1.967

4.  Two cases of acute myeloblastic leukemia evolving from aplastic anemia.

Authors:  Akihiko Taguchi; Takayuki Tominaga; Yoshitaka Nakamori; Mutsuko Miyazaki; Kenji Shinohara
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

5.  Aplastic anaemia: an analysis of 174 patients.

Authors:  M A Mir; C G Geary
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

Review 6.  Androgens and erythropoiesis: past and present.

Authors:  S Shahani; M Braga-Basaria; M Maggio; S Basaria
Journal:  J Endocrinol Invest       Date:  2009-04-07       Impact factor: 4.256

Review 7.  Recent developments in the toxicology of anabolic steroids.

Authors:  S Graham; M Kennedy
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

8.  Oxymetholone treatment in myelofibrosis.

Authors:  R Hast; L Engstedt; S Jameson; A Killander; B Lundh; P Reizenstein; K O Skårberg; A M Udén; B Wadman
Journal:  Blut       Date:  1978-07-14

9.  Treatment of severe aplastic anemia with antilymphocyte globulin and androgens: a report on 33 patients.

Authors:  T Facon; M P Walter; P Fenaux; P Morel; B Dupriez; C Gardin; J P Jouet; F Bauters
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

10.  Anabolic steroids and bone marrow toxicity during therapy with methotrexate.

Authors:  R G Rawbone; K D Bagshawe
Journal:  Br J Cancer       Date:  1972-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.